MCM
USNA icon

Matarin Capital Management’s Usana Health Sciences USNA Stock Holding History

Matarin Capital Management’s Portfolio USNA Stock Details USNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.18M Sell
41,208
-21,065
-34% -$1.63M 0.78% 46
2020
Q3 		$4.59M Sell
62,273
-8,520
-12% -$684K 0.96% 22
2020
Q2 		$5.2M Sell
70,793
-56,271
-44% -$4.41M 1.04% 14
2020
Q1 		$7.34M Sell
127,064
-7,208
-5% -$501K 1.14% 8
2019
Q4 		$10.5M Sell
134,272
-57,218
-30% -$4.22M 1.01% 15
2019
Q3 		$13.1M Buy
191,490
+39,718
+26% +$2.67M 0.99% 19
2019
Q2 		$12.1M Buy
151,772
+12,804
+9% +$1.02M 0.86% 37
2019
Q1 		$11.7M Sell
138,968
-3,743
-3% -$391K 0.85% 36
2018
Q4 		$16.8M Sell
142,711
-7,922
-5% -$916K 1.36% 3
2018
Q3 		$18.2M Buy
150,633
+11,191
+8% +$1.39M 1.17% 11
2018
Q2 		$16.1M Sell
139,442
-17,442
-11% -$1.91M 1.16% 9
2018
Q1 		$13.5M Buy
156,884
+5,112
+3% +$396K 1.01% 19
2017
Q4 		$11.2M Sell
151,772
-14,642
-9% -$979K 0.88% 32
2017
Q3 		$9.6M Buy
166,414
+33,613
+25% +$1.99M 0.82% 38
2017
Q2 		$8.51M Sell
132,801
-4,628
-3% -$285K 0.79% 37
2017
Q1 		$7.92M Sell
137,429
-9,163
-6% -$547K 0.78% 37
2016
Q4 		$8.97M Buy
146,592
+1,082
+0.7% +$70.5K 1.01% 14
2016
Q3 		$10.1M Buy
145,510
+6,442
+5% +$425K 1.11% 8
2016
Q2 		$7.75M Sell
139,068
-1,352
-1% -$81.5K 1.05% 11
2016
Q1 		$8.52M Buy
140,420
+9,274
+7% +$546K 1.19% 5
2015
Q4 		$8.38M Buy
131,146
+15,896
+14% +$1.03M 1.25% 5
2015
Q3 		$7.72M Buy
115,250
+41,632
+57% +$2.94M 1.58% 6
2015
Q2 		$5.03M Buy
73,618
+4,684
+7% +$297K 1.44% 3
2015
Q1 		$3.83M Buy
68,934
+12,290
+22% +$630K 1.16% 8
2014
Q4 		$2.91M Buy
56,644
+1,040
+2% +$51.1K 1.27% 10
2014
Q3 		$2.05M Buy
55,604
+894
+2% +$32.3K 0.94% 24
2014
Q2 		$2.14M Buy
54,710
+10,198
+23% +$378K 0.95% 23
2014
Q1 		$1.68M Buy
44,512
+7,980
+22% +$279K 0.99% 30
2013
Q4 		$1.38M Buy
36,532
+12,086
+49% +$462K 0.85% 61
2013
Q3 		$1.06M Buy
+24,446
New +$981K 0.89% 46

Other funds holding USNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Matarin Capital Management's USNA Position: Q4 2020 in Review

Matarin Capital Management reduced its Usana Health Sciences (USNA) stake by 34% in Q4 2020, selling an estimated $1.63M and leaving 41,208 shares worth $3.18M. The position accounts for 0.78% of the portfolio, ranked #46.

Matarin Capital Management first reported a position in USNA in Q3 2013 and has held it in 30 quarters since. The position peaked at $18.2M in Q3 2018. 191 funds tracked by Wall St. Rank hold USNA as of Q4 2020.

  • Matarin Capital Management held 41,208 shares of Usana Health Sciences worth $3.18M as of Q4 2020.
  • Matarin Capital Management sold 21,065 Usana Health Sciences shares in Q4 2020, an estimated $1.63M.
  • Usana Health Sciences made up 0.78% of Matarin Capital Management's portfolio in Q4 2020, its #46 holding.
  • Matarin Capital Management first reported a position in Usana Health Sciences in Q3 2013 and has held it in 30 quarters since.
  • Matarin Capital Management's Usana Health Sciences position peaked at $18.2M in Q3 2018.
  • 191 funds tracked by Wall St. Rank held Usana Health Sciences as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.